Cereno Scientific AB announced that Julia Fransson has joined the company as Director of Business Development. She joins the clinical stage biotech at an exciting point of the company's growth journey, in developing innovative treatments for common and rare cardiovascular disease, with lead candidate drug CS1 in phase II in orphan disease PAH which is to deliver top line study results by Second Quarter this year. Julia Fransson is an experienced business development professional in the life science industry.

She is skilled in crafting strong and focused strategies, translating key scientific and market insights toward investors and partners as well as business modelling market analysis and biotech asset valuation. Previous roles include management positions within developing technology companies as well as, most recently, heading up a boutique life science strategy advisory firm. Julia holds a B.Sc.

in Biotechnology and a M.Sc. in Business Design in life science companies from Chalmers University of Technology, Sweden.